Joseph Oliveto
Known title: President and CEOCIK: 0001437782
Associated companies
Transaction History
| MIST | ▼ Sell | Open Market | 36,500 | $82K | 4/16/2026 | View on chart |
| MIST | ▲ Buy | Option Exercise | 66,600 | — | 1/26/2026 | View on chart |
| MIST | ▼ Sell | Open Market | 34,523 | $67K | 1/26/2026 | View on chart |
| MIST | ▼ Sell | Open Market | 43,000 | $97K | 1/8/2026 | View on chart |
| MIST | ▼ Sell | Open Market | 500 | $1K | 1/7/2026 | View on chart |
| MIST | ▼ Sell | Open Market | 133,054 | $309K | 12/15/2025 | View on chart |
| MIST | ▲ Buy | Grant | 280,000 | — | 12/12/2025 | View on chart |
| MIST | ▲ Buy | Grant | 66,666 | — | 7/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial
Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.
Milestone Enrolls First Canadian Participant in Phase 3 AFib Trial. Milestone Pharmaceuticals reported that the first Canadian participant has been enrolled in its ReVeRA‑301 Phase 3 trial of the epiripamil nasal spray for atrial fibrillation with rapid ventricular response. The enrollment marks a key step toward the pivotal study that will evaluate the drug’s efficacy and safety in a larger population. The company’s progress in this trial could influence future regulatory decisions and market perception of the product.